Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRONPAD
2024-514593-50-00Phase 4Authorised
- Sponsor
- Biobizkaia Health Research Institute
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferric carboxymaltose in iron deficiency anemia (IDA), anaemia and arteriosclerosis obliterans (2 arms), sponsored by Biobizkaia Health Research Institute. Primary endpoint: Incidence of blood transfusion. Planned start May 2024; status: authorised.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)anaemiaarteriosclerosis obliterans
Beyond the preview
Go deeper on 2024-514593-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514593-50-00.